DNA

Part:BBa_K5124024

Designed by: Louise Brown   Group: iGEM24_Exeter   (2024-08-19)


Cas13a CXCL8_target for transcription

Usage and Biology

The Exeter iGEM 2024 team are designing a rapid detection system for Bovine Tuberculosis (bTB) using CRISPR-Cas detection systems. The literature suggests that bTB infection in cattle can be detected by nucleic acid biomarkers in both blood [1] and tissue samples [2]. Therefore, there was potential to develop tests looking for both DNA and RNA biomarkers in infected cattle.

In 2021 McLoughlin et al. published RNA-Seq data from cattle infected with bTB at several timepoints during the disease progression [1]. They identified 19 potential biomarkers that were present across the entire length of the infection time course. We would have liked to have tested all 19 sequences but after two rounds of the design-build-test-learn cycle (see our Wiki) we focused on:
CXCL8- chemokine ligand 8, involved in infection response and tissue injury.
FOSB- FBJ murine osteosarcoma viral oncogene homologue B, plays a role in regulating cell proliferation, differentiation and transformation.
NR4A1- nuclear receptor subfamily 4, group A, member 1, plays a role in inflammation and apoptosis.
PLAUR- plasminogen activator, urokinase receptor, a biomarker of inflammation.
RGS16- regulator of G-protein signalling 16, linked to several disease states.

This composite part contains a 5’ T7 promoter and a target sequence; a 150-nucleotide RNA sequence from the Bos taurus genome (BioProject accession number PRJNA450837). Once transcribed this sequence contains a 20-nucleotide sequence that is complimentary to the spacer sequence CXCL8 (see basic part BBa_K5124018 for details). This target sequence was used in our Cas13a assays as a mimic of bTB infected samples from cattle. In the final detection system, this part could be used as a positive control.

Design and Characterisation

This sequence was synthesised by IDT as a composite part containing a 5’ T7 promoter (BBa_K5124041) and Type IIs compatible prefix and suffixes. As we needed the RNA sequence be identical to the Bos taurus genome, we were unable to remove the XbaI and PstI restriction enzyme sites. The g-block was cloned into a high copy plasmid (origin of replication from pUC18 [3]) carrying an ampicillin selection marker.

The respective sgRNA part is BBa_K5124035

Results

Results from in-vitro transcription reactions are shown below.

Figure 2: Image of the Agilent Tapestation 4200 RNA ScreenTape gel from final T7 in vitro transcription – showing uniformity among variants of each RNA component.

All columns on the RNA tape showed there was RNA present around the expected length for sgRNA, and target RNA.

Figure 3: Shows CXCL8 target sequence (#8) normalised sample intensity graph, from final T7 in vitro transcription.

Due to the small size of the target RNA sequence and the upper marker in the sample buffer being degraded, the length of RNA sequences will not be accurate. (See Figure above showing uniformity among variants of each RNA component.) A 153-target nucleotide peak was expected,  the peak at 75 nucleotides demonstrates that a short RNA was transcribed. We were happy that this demonstrates successful transcription of our RNA. . There is also a large board peak, above 2000 bp, which is likely from environmental contamination. The concentration of CXCL8 target RNA was determined to be 64.4 ng/ul which was a usable concentration for our final tests.​

Results from our final tests are shown below.

Figure 4: A graph showing successful results from our final tests

We mixed our Cas13a, an sgRNA, the corresponding target RNA and our fluorescent probes and saw an increase in fluorescence with time for PLAUR, CXCL8, RGS16 and NR4A1. Tis shows that when activated by the correct sgRNA Cas13a binds to the target and cleaves the probe. However, there was no increase in fluorescence for FOSB. This is because we discovered a mistake in the folding of the FOSB sgRNA. However this proved beneficial as it shows that if the sgRNA does not fold correctly Cas13a cannot cleave the probes.

Conclusion

We successfully expressed our Cas13a enzyme and achieved reasonable purity. We can tell the Cas13a system worked because we got positive results when the Cas13a, sgRNA, target and probe were added together (as shown in the graph above), but also because we had negative controls that caused no reaction. These were:
The system missing one of the 4 parts showing all parts are necessary.
The system with the wrong target showing that the system only activates with the correct RNA sequence (data not shown on this graph please see Measurement section on Wiki).
The system with the spacer FOSB which folded incorrectly, showing the testing for the folding of sequences was necessary.

References

1. McLoughlin KE, Correia CN, Browne JA, Magee DA, Nalpas NC, Rue-Albrecht K, et al. RNA-Seq Transcriptome Analysis of Peripheral Blood From Cattle Infected With Mycobacterium bovis Across an Experimental Time Course. Frontiers in Veterinary Science. 2021; 8:662002.

2. Taylor GM, Worth DR, Palmer S, Jahans K, Hewinson RG. Rapid detection of Mycobacterium bovis DNA in cattle lymph nodes with visible lesions using PCR. BMC Vet Res. 2007 Jun 13; 3:12.

3. Vieira J, Messing J. The pUC plasmids, an M13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers. Gene. 1982 Oct; 19(3):259-68.

Sequence and Features


Assembly Compatibility:
  • 10
    INCOMPATIBLE WITH RFC[10]
    Illegal XbaI site found at 33
    Illegal PstI site found at 128
    Illegal PstI site found at 146
  • 12
    INCOMPATIBLE WITH RFC[12]
    Illegal PstI site found at 128
    Illegal PstI site found at 146
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    INCOMPATIBLE WITH RFC[23]
    Illegal XbaI site found at 33
    Illegal PstI site found at 128
    Illegal PstI site found at 146
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal XbaI site found at 33
    Illegal PstI site found at 128
    Illegal PstI site found at 146
  • 1000
    COMPATIBLE WITH RFC[1000]


[edit]
Categories
Parameters
None